A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Hematologic Malignancy
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Phase 1a/1b study will be conducted to evaluate the tolerability, safety, PK, PD, immunogenicity and preliminary antitumor activity of IBI322 in China. Phase 1a is dose escalation and plans to enroll approximately 39-102 subjects with hematologic malignancy who failed the standard treatment. Phase 1...
Phase 1a/1b study will be conducted to evaluate the tolerability, safety, PK, PD, immunogenicity and preliminary antitumor activity of IBI322 in China. Phase 1a is dose escalation and plans to enroll approximately 39-102 subjects with hematologic malignancy who failed the standard treatment. Phase 1b is dose expansion, and plans to enroll approximately 80 subjects with hematologic malignancy.
Tracking Information
- NCT #
- NCT04795128
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: WenBin Qian Second Affiliated Hospital, School of Medicine, Zhejiang University
Get Well Soon